Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : LastShadow's Position Trading -- Ignore unavailable to you. Want to Upgrade?

To: AlienTech who wrote (9914)	3/8/1999 1:22:00 PM
From: Susan Saline	Respond to of 43080

onsl dinnner on at <ggg> +10 now

To: AlienTech who wrote (9914)	3/8/1999 1:27:00 PM
From: John J H Kim	Respond to of 43080

Female Sexual Dysfunction Patent Granted to VIVUS; VIVUS Plans Diversification of R&D MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 8, 1999--VIVUS, Inc. (Nasdaq:VVUS) has been issued patent no. 5877216 for the "Treatment of Female Sexual Dysfunction" by the U.S. Patent Office. This patent provides VIVUS with broad protection for the commercialization of topical formulations of vasodilating agents and steroid hormones for the treatment of sexual dysfunctions effecting women. Therapeutic opportunities include treatments for women with arousal and orgasm dysfunction, the enhancement of vaginal lubrication, and the improvement of vaginal muscle tone. "This important patent underscores VIVUS' commitment to diversify its research and development efforts within urology beyond the treatment of male erectile dysfunction," stated Leland Wilson, President and CEO of VIVUS, Inc. Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as the transurethral system for erection. This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacologic agents via the urethra. Note to editors and investors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). CONTACT: VIVUS, Inc. Nina W. Ferrari, 650/934-5200 IR@VIVUS.com